Supplementary

Table S1 Comparison of myeloprotection data with global studies (G1T28-02 and G1T28-05) (+ EP regimen)

Parameters	RWS	G1T28-02		G1T28-05	
	Trilaciclib + EP (N=26)	Placebo + EP (N=37*)	Trilaciclib + EP (N=38*)	Placebo + EP/A (N=53)	Trilaciclib + EP/A (N=54)
SN, n (%)	1 (3.8)	16 (43.2)	2 (5.3)	26 (49.1)	1 (1.9)
Grade 3/4 neutropenia, n (%)	6 (23.1)	31 (83.8)	15 (41.7)	39 (73.6)	17 (31.5)
Grade 3/4 anemia, n (%)	2 (7.7)	3 (8.1)	3 (7.9)	15 (28.3)	10 (18.5)
Grade 3/4 thrombocytopenia, n (%)	1 (3.8)	6 (16.2)	2 (5.3)	20 (37.7)	1 (1.9)
Antibiotics, n (%)	4 (15.4)	18 (48.6)	16 (42.1)	25 (47.2)	21 (38.9)
G-CSF, n (%)	11 (42.3)	24 (64.9)	4 (10.5)	25 (47.2)	16 (29.6)
RBC infusion at ≥ week 5, n (%)	0	9 (24.3)	2 (5.3)	11 (20.8)	7(13)
ESA, n (%)	3 (11.5)	2 (5.4)	1 (2.6)	6 (11.3)	3 (5.6)
TPO, n (%)	1 (3.8)	–	–	–	–
Platelet infusion, n (%)	0	0	2 (5.3)	2 (3.8)	1 (1.9)
Infection SAE, n (%)	2 (7.7)	2 (5.4)	4 (10.5)	7 (13.2)	3 (5.6)
Pulmonary infection SAE, n (%)	2 (7.7)	1 (2.7)	4 (10.5)	5 (9.4)	2 (3.7)
FN, n (%)	0	3 (8.1)	1 (2.6)	3 (5.7)	1 (1.9)

*, one patient in each group has been randomized but not treated. EP/A, platinum/etoposide/atezolizumab; EP, platinum/etoposide; ESA, erythrocyte-stimulating agent; FN, febrile neutropenia; G-CSF, granulocyte-stimulating factor; RWS, real-world study; SAE, serious adverse event; SN, severe neutropenia; TPO, thrombopoietin.

Table S2 Myeloprotection data with global studies (G1T28-03) (+ TPT regimen)

Parameters	Placebo + TPT (1.5 mg/m^2) (N=29)	G1T28-03, trilaciclib + TPT (1.5 mg/m^2) (N=32)
SN, n (%)	22 (75.9)	13 (40.6)
Grade 3/4 neutropenia, n (%)	24 (82.8)	22 (68.8)
Grade 3/4 anemia, n (%)	17 (58.6)	9 (28.1)
Grade 3/4 thrombocytopenia, n (%)	16 (55.2)	17 (53.1)
Antibiotics, n (%)	8 (27.6)	7 (21.9)
G-CSF, n (%)	19 (65.5)	16 (50)
RBC infusion at ≥ week 5, n (%)	12 (41.4)	10 (31.3)
ESA, n (%)	6 (20.7)	1 (3.1)
Platelet infusion, n (%)	9 (31)	8 (25)
Infection SAE, n (%)	3 (10.3)	1 (3.1)
Pulmonary infection SAE, n (%)	1 (3.4)	1 (3.1)
FN, n (%)	5 (17.2)	2 (6.3)

ESA, erythrocyte-stimulating agent; FN, febrile neutropenia; G-CSF, granulocyte-stimulating factor; N, total number of patients; NA, not available; RBC, red blood cell; RWS, real-world study; SAE, serious adverse event; SN, severe neutropenia; TPO, thrombopoietin; TPT, topotecan.

https://dx.doi.org/10.21037/jtd-24-893